Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) fell 4.6% during mid-day trading on Monday . The stock traded as low as $4.58 and last traded at $4.58. 686,579 shares were traded during trading, an increase of 626% from the average session volume of 94,574 shares. The stock had previously closed at $4.80.
Innovent Biologics Stock Performance
The firm’s 50 day moving average is $5.02 and its 200-day moving average is $5.18.
About Innovent Biologics
Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.
Read More
- Five stocks we like better than Innovent Biologics
- What Are Earnings Reports?
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- Stock Market Sectors: What Are They and How Many Are There?
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- Learn Technical Analysis Skills to Master the Stock Market
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
